BioMarin Q1 revenue rises, beats estimates

ReutersMay 4, 2026 8:18 PM

View all comments（0）



Overview

US rare disease drugmaker's Q1 revenue rose 3% yr/yr, beating analyst expectations
Adjusted EPS for Q1 beat consensus
Company raised 2026 revenue guidance after Amicus acquisition added new products

Outlook

BioMarin raises 2026 total revenue guidance to $3.825 bln-$3.925 bln, up from $3.325 bln-$3.425 bln
Company lowers 2026 Non-GAAP diluted EPS guidance to $4.85-$5.05 from $4.95-$5.15
More than 55% of 2026 revenue and two-thirds of Non-GAAP EPS expected in 2H26

Result Drivers

ENZYME THERAPIES GROWTH - Revenue growth in Q1 was driven by increased sales of VIMIZIM, NAGLAZYME, and BRINEURA, and new patient demand for PALYNZIQ following label expansion
PORTFOLIO EXPANSION - Addition of GALAFOLD and POMBILITI + OPFOLDA from Amicus acquisition strengthened and accelerated growth outlook
HIGHER OPERATING COSTS - Increased SG&A and R&D expenses, a $31 mln NAGLAZYME manufacturing charge, and costs tied to Amicus deal weighed on profitability

Company press release: ID:nPn8GWjsBa

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q1 Revenue	Beat	$766 mln	$756 mln (21 Analysts)
Q1 Adjusted EPS	Beat	$0.76	$0.75 (16 Analysts)
Q1 EPS		$0.54
Q1 Net Income		$106 mln

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Comments (0)

Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.

Commenting Guidelines

Recommended Articles

Trump’s China Visit Boosts China Stocks Nearly 4%, Alibaba Favored by AI Bets Despite Weak Results

TradingKey - On May 13 (ET), U.S. President Trump arrived in Beijing to begin a three-day visit. Markets expect both sides to engage in dialogue on issues such as trade and technology, a move that has eased concerns over a further escalation of U.S.-China tensions.

Pricing Hiked Three Times to $185. What Gives Cerebras Confidence in Its $49B Valuation After Spurning SoftBank?

TradingKey - AI chipmaker Cerebras Systems is racing toward a US IPO with momentum far exceeding expectations, as Wall Street's fervor for the AI semiconductor sector is fully reflected in the company.

AI Frenzy vs. Crypto Winter: Cerebras Sets Year’s Largest IPO as Crypto Funding Hits Freezing Point

Market capital is exhibiting a powerful "siphon effect," as funds flow continuously toward AI hardware and infrastructure with clearer technological pathways and more defined revenue models. Conversely, the cryptocurrency sector has fallen out of favor due to the absence of these attributes. This suggests that if crypto enterprises can integrate AI development—such as the AI agent economy—they may have an opportunity to break through the current IPO freeze.

Cerebras Systems IPO 2026: Date, Price, Valuation, and Whether CBRS Is Worth Buying

TradingKey - Cerebras Systems (CBRS) IPO prices May 13–14 at $125–$135/share. $26–$27B valuation, 20x oversubscribed, $510M revenue, 47% net margin, OpenAI 750MW deal. Everything you need to know.

AMD Q1 Earnings: Data Center Revenue Surges 57% Driving Results Above Estimates, Shares Rise Over 16% After Hours

TradingKey - On May 5 (ET), Advanced Micro Devices (AMD) released its first-quarter fiscal 2026 financial results after the market close. The company reported revenue of $10.253 billion, up 38% year-over-year, exceeding market expectations of $9.89 billion. Non-GAAP earnings per share (EPS) were $1.

Featured Tools